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 Abstract: 
We studied single nucleotide polymorphisms (SNPs) and haplotypes in the urotensin-II 
(UTS2) and urotensin-II receptor gene (UTS2R) in Hong Kong Chinese (224 hypertensive 
and 306 normotensive unrelated subjects) and their relation to hypertension and the metabolic 
syndrome. For UTS2, the GGT haplotype (–605G, 143G, 3836T) was associated with higher 
plasma level of U-II and insulin, and higher homeostasis model assessment of insulin 
resistance index and β-cell function.  For UTS2R, the AC haplotype (-11640A, -8515C) was 
associated with higher 2-hour plasma glucose after a 75-g oral glucose load. Therefore, U-II 
and its receptor may play a role in insulin resistance. 
  
[100 words]  




 1. Introduction 
U-II is the most potent vasoconstrictor known and is more potent than endothelin-1 (ET-1) 
[3].  Human U-II is an 11 amino acid cyclic peptide and is derived from a precursor 
molecule, prepro-U-II [22,23].  The gene encoding the peptide, UTS2, is located at 1p36 and 
contains 5 exons. U-II acts through a G-protein-coupled receptor, the UT receptor [3].  The 
gene encoding the receptor, UTS2R, is located at 17q25.3 and is intronless [24]. 
 
U-II circulates in human plasma and its plasma level is elevated in renal failure [41], 
congestive heart failure [16,21,27,28], portal hypertension caused by liver cirrhosis [14] and 
diabetes mellitus [39].  We previously reported that plasma U-II level is raised in 
hypertensive patients compared to normotensive controls and is directly related to the systolic 
blood pressure [8].  On the other hand, the elevation in plasma U-II level in diabetic patients 
is independent of the level of blood glucose [39].  U-II inhibits insulin secretion in the rat 
pancreas [31].  In Type 2 diabetic patients, plasma and urinary U-II level is higher in those 
with renal dysfunction than those with normal renal function [40].   
 
A single nucleotide polymorphism (SNP) in UTS2, 143G>A (rs228648), is associated with 
susceptibility to type 2 diabetes in Han Chinese [36,48].  Another SNP, 3836C>T 
(rs2890565) is associated with increased insulin resistance and susceptibility to type 2 
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 diabetes in Japanese [37,45].  However, in previous studies of SNPs in UTS2 [36,37,45,48] 
there are no reports of SNPs in the promoter and haplotype analysis, and the influence of 
these SNPs on plasma U-II level has not been investigated.  For the UT receptor, there is 
only one report of SNP study in Japanese population in which no SNP can be found in the 
coding region and the two SNPs in promoter region, -7836G>A and -7814C>T did not show 
any association with type 2 diabetes mellitus and related clinical parameter.  Therefore, we 
hypothesized that U-II may play a role in the development of hypertension and metabolic 
syndrome, which is a cluster of metabolic abnormalities, associated with central (abdominal) 
obesity, raised fasting plasma glucose, raised blood pressure, raised triglycerides and reduced 
HDL cholesterol [2].  In this study, we sequenced the UTS2 promoter for novel SNPs, and 
investigated the association of haplotypes and SNPs in the UTS2 gene with hypertension and 
clinical parameters important in metabolic syndrome, such as insulin resistance, plasma 
glucose, plasma insulin, lipid profile and blood pressure, etc.  We also investigated the 
association of two known SNPs in the UTSR2 gene promoter, -11640G>A (rs7502620) and 
-8515T>C (rs7211435) which has been documented in the HapMap database, with the 
clinical parameters. 
 
2. Subjects and Methods 
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 2.1 Subjects 
The study protocol had been approved by the Institutional Review Board of the University of 
Hong Kong/Hospital Authority Hong Kong West Cluster.  We studied 224 hypertensive 
patients and 306 normotensive controls with their informed consent.  The subjects were all 
unrelated Hong Kong Chinese.  Hypertensive subjects were recruited from the Hypertension 
Clinic of a teaching hospital. Hypertension was defined as systolic blood pressure 
≥140mmHg, or a diastolic blood pressure ≥90mmHg on at least 3 separate occasions.  
Patients on treatment who were previously diagnosed as hypertensive by the above criteria 
were also eligible.  Patients with secondary hypertension (e.g. renal artery stenosis, 
coarctation, glomerulonephritis, pyelonephritis, phaeochromocytoma, Cushing’s syndrome, 
Conn’s syndrome) were excluded.  Normotensive controls were recruited from a cohort of 
subjects previously randomly recruited from the general population [9,15]. 
 
Physical examination (including measurement of height, weight, body fat, waist and hip 
circumference), urine analysis and ECG were performed and a full medical history (including 
past medical history, drug history, family history, smoking status, alcohol intake and exercise 
habit) was obtained.  Bioelectrical impedance was measured as an estimate of percentage 
body fat (Tanita TBF-531, Tanita Corporation, Tokyo, Japan).  Lipid profile, fasting glucose, 
insulin and 2-hour glucose after a 75-g oral glucose load were measured. Insulin resistance 
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 was assessed with the homeostasis model assessment of insulin resistance index (HOMA-IR), 
which is the product of the fasting plasma insulin (FPI) (mIU/L) and fasting plasma glucose 
(FPG) (mmol/L) divided by 22.5 [18].  Pancreatic β-cell function, estimated as HOMA-β%, 
is given by (20xFPI)/(FPG–3.5).   
 
Subjects were studied in the morning after overnight fasting.  The blood pressure of each 
patient was measured using a mercury sphygmomanometer by a trained nurse manually after 
the subject had been sitting and resting for at least 5 minutes. Blood pressure was measured 
three times at 5 minute intervals. The first blood pressure measurement was to familiarise the 
patient with the procedure and the sensation of the inflated cuff.  The 2 subsequent systolic 
and phase V diastolic blood pressure readings were recorded to the nearest 2mmHg.  The 
mean of the 2 readings was used in data analysis.  
 
After sitting or resting for at least 5 minutes, 20ml venous blood was taken from a forearm 
vein for a full blood count (haemoglobin, haematocrit, white blood count, differential white 
count and platelet count), renal and liver function tests (sodium, potassium, urea, creatinine, 
glucose, total bilirubin, total protein, albumin, ALT and alkaline phosphatase), plasma insulin 
and lipid profile.  In 29 hypertensive subjects and 54 control subjects, 10 ml venous blood 
was placed in a pre-chilled EDTA bottle and placed on ice immediately. In an adjacent room, 
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 the blood was immediately centrifuged at 4°C to obtain the buffy coat and the plasma was 
frozen at –70°C until the time of assay.  Plasma U-II was measured by radioimmunoassay as 
described previously [8]. 
 
2.2 Genomic DNA Amplification and SNP identification 
Genomic DNA was extracted from the buffy coat using the QIAamp DNA Mini Kit (Qiagen, 
Hilden, Germany) according to the manufacturer's protocol.  Candidate SNPs were selected 
from the dbSNP database and their locations are shown in Figure 1.  Genomic sequence was 
obtained from GenBank (accession numbers NT021937 and NT010663).  To sequence a 
1,600-bp UTS2 promoter region, three primer sets were designed.  PCR reactions were 
performed in 22-27 subjects using primers, U2P1 (5’-AGT GAC GCA GAG CAT AAG ATG 
A-3’) and U2P2 (5’-CAC CAC ACC TGG TTA ATT GTT G-3’) to amplify a 1019bp from 
+120 to -899,  U2P3 (5’-CTG GGC AAC ATA GAG AAA CAC-3’) and U2P4 (5’-CCT 
CCT GTC TCA ATT TTT TTC-3’) to amplify a 627bp segment from -525 to -1151, and 
U2P5 (5’-AGA CAA GAC ACA AAT CAC ACA G-3’) and U2P6 (5’-AGT TTT GCT CTT 
GCC ACC C-3’) to amplify a 534bp segment from -1109 to -1642.  The SNPs in the UTS2 
promoter region were identified by direct sequencing using ABI 3730 DNA Analyzer 
(Applied Biosystems, Foster City, USA). 
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 2.3 Genotyping 
High-throughput genotyping of the SNPs in UTS2 (except -605G>A and -788C>T) and 
UTS2R were performed using the Sequenom MassARRAY system (Sequenom, San Diego, 
CA) which utilizes Matrix Assisted Laser Desorption Ionization-Time Of Flight 
(MALDI-TOF) technology.  
 
Genotyping of -605G>A and the novel SNP, -788C>T in UTS2, were performed using FokI 
and MwoI (New England Biolabs, Beverly, MA) to generate restriction fragment length 
polymorphisms (RFLP).  A 375bp fragment incorporating these 2 SNPs (-525 to -899) was 
amplified from genomic DNA using primers, U2P2 and U2P3.  A single FokI site and 2 
MwoI sites are present within this 375bp fragment (Figure 2).  The -605G>A substitution 
eliminates the FokI site while -788C>T substitution eliminates one of the 2 MwoI sites.  The 
PCR product was digested with either FokI or MwoI for 4 hours at 37oC or 60oC respectively. 
The digested products were analyzed by gel electrophoresis in 10% polyacrylamide gels. 
 
2.4 Statistical analysis 
Data were analysed using a statistical software programme (SPSS for Windows, ver. 11.0, 
SPSS Inc., Chicago, USA).  Genotype frequencies for each SNP were tested for 
Hardy-Weinberg equilibrium.  As the distributions of fasting plasma insulin, HOMA-IR and 
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 HOMA-β% were skewed, these were expressed as geometric means with 95% confidence 
intervals (CIs).  Comparison of clinical characteristics was performed using unpaired 
student’s t test or Mann-Whitney U test for continuous variables, and Chi-square test for 
categorical variables. Stepwise multiple regression analysis was performed with HOMA-IR 
as the dependent variable.  The predictor variables examined included sex, age, body mass 
index (BMI) and plasma U-II level.  The programme Haploview (ver. 3.2) was used to 
assess linkage disequilibrium for all possible SNP pairs by determining r2 [5].  Haplotypes 
were predicted using the programme PHASE (ver. 2.1.1), which implements a Bayesian 
method for estimating haplotypes from population genotype data [7,33,34].  For haplotype 
analysis, subjects who carried a particular haplotype with a probability ≥0.95 were also 
included.  Analysis of covariance (ANCOVA) was used for comparing the fasting plasma 
insulin, HOMA-IR, HOMA-β%, plasma U-II level and 2-hour plasma glucose of groups with 
different haplotypes, with age, sex, BMI and HOMA-IR as covariates where indicated.  A 
2-tailed p-value less than 0.05 was considered statistically significant.  
 
3. Results 
3.1 Baseline characteristics 
We studied 224 hypertensive subjects and 306 normotensive controls. Their baseline 
characteristics are shown in Table 1.  There were as expected, significant differences in 
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 blood pressure, weight, BMI, percentage body fat, plasma cholesterol level, fasting plasma 
glucose, fasting plasma insulin, HOMA-IR, HOMA-β%, plasma U-II level and the 
prevalence of diabetes mellitus and metabolic syndrome according to the NCEP ATP III 
guidelines [20].  Genotyping of the two SNPs -11640G>A and -8515T>C in UTS2R were 
performed in only 174 normotensive controls and 114 hypertensive subjects. 
 
3.2 Plasma U-II level and HOMA-IR 
Plasma U-II level correlated with ln [HOMA-IR] (r=0.242, p=0.027).  In stepwise multiple 
regression analysis, ln [HOMA-IR] was related to plasma U-II level (β=0.23, p=0.020), sex 
(β=0.30, p=0.005) and BMI (β=0.47, p<0.001).  These variables explain 25.8% of the 
variation in HOMA-IR (p<0.001). 
 
3.3 Identification of SNPs in UTS2 promoter by direct sequencing 
Five SNPs were identified in the promoter region of UTS2 by direct sequencing.  A novel 
(C>T) SNP was found at position -788 which has not been reported before.  The other SNPs 
(-18C>T, -605G>A, -1263C>T and -1477C>T) have been reported in the dbSNP database 
previously and showed heterozygosity in our population.  However, the minor allele 
frequencies of -18C>T and -1477C>T were less than 5% and therefore not further analysed.  
Two SNPs (-660C>T and -789G>A) previously identified in African Americans as described 
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 in the dbSNP database were homozygous in our sample.  
 
3.4 SNP genotyping  
The -605G>A and -788C>T variants were genotyped by FokI-RFLP (Figure 3a) and 
MwoI-RFLP (Figure 3b) respectively, while other SNPs in UTS2 (-1263C>T, 143G>A and 
3836C>T) and UTS2R (-11640G>A and -8515T>C) were genotyped using the Sequenom. 
The results are shown in Table 2.  For each SNP, the observed genotype frequencies showed 
no significant deviation from Hardy-Weinberg equilibrium.   
 
3.5 Linkage disequilibrium 
In this study, r2 was used to measure linkage disequilibrium as it is independent of allele 
frequency and appropriate for modest sample sizes [13,29].  The average r2 value across the 
UTS2 gene was 0.18. The SNPs, -605G>A and 143G>A are in almost complete linkage 
disequilibrium (r2 = 0.99).  For UTS2R, the 2 SNPs, -11640G>A and -8515T>C are also in 
almost complete linkage disequilibrium (r2 = 0.99). 
 
3.6 Single variant analysis of UTS2 
Plasma U-II level was related to 3836C>T (Table 3, p=0.006 after adjusting for sex, age and 
BMI), especially among the normotensive subjects (p=0.002 and after adjustment, p=0.002).  
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 Plasma U-II level was not significantly related to -1263C>T, -788C>T, -605G>A or 143G>A 
(Table 3).  
 
The 3 SNPs, -605G>A, 143G>A and 3836C>T were significantly associated with 
HOMA-β% (Table 4).  3836C>T was also significantly associated with higher fasting 
plasma insulin and HOMA-IR.  The associations remained significant after adjusting for sex, 
age and BMI (p=0.024, 0.038 and 0.040 for plasma insulin, HOMA-IR and HOMA-β% 
respectively).  However, none of the SNPs studied was associated with hypertension (Table 
2), waist circumference, plasma triglyceride, plasma cholesterol, plasma HDL cholesterol, 
fasting plasma glucose or blood pressure (p>0.05).  
 
3.7 Haplotype analysis of UTS2 
The most common five-locus haplotypes, comprising the five nucleotide variants at positions 
-1263, -788, -605, 143 and 3836, and their frequencies were CCGGC (0.31), CCGGT (0.30), 
CCAAC (0.24), CTAAC (0.09), TCGGC (0.03) and CTAAT (0.02).  As the 3 most common 
five-locus haplotype differs only at the three SNPs, -605G>A, 143G>A and 3836C>T and 
only these three SNPs showed some associations with clinical parameters, three-locus  
haplotypes made up of –605G>A, 143G>A and 3836C>T were constructed for further 
analysis.  The most common three-locus haplotypes and their frequencies were GGC (0.35), 
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 AAC (0.33), GGT (0.30) and AAT (0.02).  Carriers of GGT haplotype had higher fasting 
plasma insulin, HOMA-IR and HOMA-β% (Table 4).  The association remained significant 
after adjusting for age, sex and BMI (p=0.029, 0.045 and 0.049 respectively).  Moreover, the 
fasting plasma insulin, HOMA-IR and HOMA-β% increased with number of GGT haplotype 
(p=0.017, 0.032 and 0.021).  Among non-diabetic normotensive subjects, the GGT 
haplotype was only associated with higher fasting plasma insulin and HOMA-IR, but not 
HOMA-β% (p=0.038, 0.026 and 0.274 respectively and after adjusting for age, sex and BMI, 
p=0.037, 0.024 and 0.309 respectively).  However, none of the haplotypes studied was 
associated with hypertension, waist circumference, plasma triglyceride, plasma cholesterol, 
plasma HDL cholesterol, fasting plasma glucose or blood pressure (p>0.05).  
 
Carriers of GGT haplotypes had higher plasma U-II level (Table 3, p=0.016 after adjusting 
for sex, age and BMI), especially among the normotensive subjects (p=0.006 and after 
adjustment, p=0.007). 
 
3.8 Single variant and haplotype analysis of UTS2R 
Both the two SNPs, -11640G>A and -8515T>C were significantly associated with higher 
2-hour plasma glucose after a 75-g oral glucose load (Table 5).  The associations remained 
significant after adjusting for sex, age and BMI (p=0.024 for both -11640G>A and 
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 -8515T>C).  The most common 2-locus haplotypes, comprising nucleotide variants at 
positions -11640 and -8515, and their frequencies were GT (0.70) and AC (0.30).  The AC 
haplotype showed similar results as the corresponding single variant (Table 5).  The 
association of AC haplotype with 2-hour plasma glucose remained significant after adjusting 
for.sex, age, BMI and HOMA-IR (p=0.020) and is more significant among the non-diabetic 
normotensive subjects (p=0.001 and after adjustment, p=0.016).  However, none of the 
SNPs and haplotypes studied was associated with hypertension, waist circumference, plasma 
triglyceride, plasma HDL cholesterol, blood pressure, fasting plasma glucose, fasting plasma 
insulin, HOMA-IR and HOMA-β%, (p>0.05).  
 
4. Discussion  
The most important findings of this study were the associations of haplotypes and SNPs in 
the UTS2 gene with plasma U-II level, insulin resistance and pancreatic β-cell function and 
that in UTS2R gene with 2-hour plasma glucose.  We previously reported that plasma U-II 
level is raised in hypertensive patients compared to normotensive controls and is directly 
related to the systolic blood pressure [8].  Hypertension and insulin resistance are commonly 
found together in overweight persons as components of the metabolic syndrome [20,26].  In 
our local population, overweight and insulin resistance are important determinants of blood 
pressure [38].  Plasma insulin level and blood pressure are correlated in untreated patients 
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 with essential hypertension but not in those with secondary hypertension [32].  Insulin 
resistance and hyperinsulinemia can raise the blood pressure by a variety of mechanisms 
including activation of the renin-angiotensin-aldosterone and the sympathetic nervous 
systems, sodium retention, volume expansion, renal damage, atherosclerosis and oxidative 
stress [12].  Impaired insulin signalling in the insulin-resistant state contributes to 
vasoconstriction.  
 
Previously, 143G>A (T21M) polymorphism was found to be associated with diabetes 
mellitus in northern Chinese [36,48].  In Japanese subjects, 3836C>T (S89N) but not 
143G>A, was reported to be significantly associated with type 2 diabetes, increased plasma 
insulin and higher HOMA-IR [37,45].  Our results on 3836C>T is consistent with that of 
Japanese study, showing the association of this polymorphism with insulin resistance.   
 
The region 1p36 in human chromosome 1 contains the susceptible locus for type 2 diabetes in 
Chinese and Japanese [11,19].  The exact disease-containing gene remains to be identified. 
The UTS2 gene is at 1p36, raising the possibility that it may be one of the genes causing the 
metabolic syndrome.  Local expressions of both U-II and UT receptor have been 
demonstrated in human pancreas [3,10,35].  In perfused rat pancreas, glucose-induced 
insulin release can be inhibited by infusion of 10nM and 100nM U-II while arginine-induced 
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 insulin release can be inhibited by infusion of 100nM [31].  This inhibition is not due to the 
vasoconstriction action of U-II but its activation of UT receptors in pancreatic β cells and 
does not affect basal insulin release [30].  In this study, the associations of SNPs and 
haplotype in UT receptor with 2-hour plasma glucose level suggest a role of UT receptor in 
the development of impaired glucose tolerance which is a precursor to diabetes mellitus.  
The AC haplotype may increase the receptor sensitivity, density or expression, thus 
enhancing the inhibitory effect of U-II on insulin secretion in response to glucose load and 
resulting in a higher 2-hour plasma glucose level.  This new finding further supports a role 
of U-II and its receptor in the regulation of insulin secretion and glucose metabolism.   
 
However, early type 2 diabetes is characterised by hyperinsulinaemia rather than impairment 
in insulin production.  Interestingly, we found that the U-II haplotype -605G\143G\3836T 
was significantly associated with higher plasma urotensin level, plasma insulin level, insulin 
resistance and β-cell function.  In non-diabetic subjects, insulin secretion normally increases 
as a compensatory adaptation under the condition of insulin resistance [43].  The mechanism 
whereby this haplotype in U-II can cause insulin resistance remains speculative at present.  
However, it has been demonstrated that U-II can increase the releases of adrenocorticotropic 
hormone (ACTH) and epinephrine through sympathoadrenal and pituitary-adrenal pathways 
[42].  The increase in ACTH may then contribute to an increase in insulin secretion.  
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 Moreover, insulin has vascular effects in addition to its metabolic effects; it induces 
endothelial-nitric-oxide-dependent vasodilatation as well as glucose uptake into peripheral 
tissues [4].  It is possible that U-II impairs both of these actions like endothelin-1 [46].   
 
In this study, we found that the U-II haplotype -605G/143G/3836T was associated with 
higher plasma U-II level.  In fact, 3836C>T was responsible for the association.  This 
nucleotide transition in codon 266 of UTS2 is associated with a change from serine to 
asparagine at amino acid position 89.  It is not known if this amino acid substitution is 
associated with an alteration in transcription, translation or secretion, and if there is alteration 
in degradation or receptor binding.  Alternatively, there might be alteration in 
immunoreactivity.  Further studies are needed to investigate this very common variant. 
 
Although U-II is a highly potent vasoconstrictor in vitro, its infusion in man does not produce 
such a response [1,47].  We and others postulate that the net effect of U-II on vascular tone 
is determined by the balance between its direct vasoconstrictor effect and its indirect 
vasodilatory effect mediated by endothelium derived relaxing factors such as nitric oxide 
[6,17,23].  In diseases characterised by endothelial dysfunction, the vasoconstriction and the 
mitogenic effect on vascular smooth muscle may predominate.  In this regard, we have 
observed that tumour necrosis factor-alpha (TNF-α) upregulates the expression of U-II and 
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 the UT receptor in endothelial cells in vitro [unpublished observations].  There is increased 
secretion of TNF-α and other inflammatory cytokines in the whole spectrum of 
cardiovascular disease and cardiovascular risk factors, including the metabolic syndrome 
[25,44].  U-II may therefore have a role in the pathogenesis of cardiovascular diseases and 
complications.  
 
Genetic association studies are prone to false positives when multiple SNPs are tested in large 
sample sizes.  Therefore, we have focussed on haplotypes made up of common alleles and 
large effect sizes.  The population in Hong Kong is 95% Chinese, so population 
stratification is unlikely to be serious.  Nevertheless, our results need to be confirmed in 
further studies in a different setting and population.   
 
In conclusion, our study showed that haplotypes and SNPs in the UTS2 and UTS2R genes in 
Hong Kong Chinese were associated with plasma U-II level, pancreatic β-cell function, 
insulin resistance and 2-hour plasma glucose although they were not associated with 
hypertension.  These suggest that U-II and its receptor may play a role in the development 
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 Table 1 Baseline characteristics of the 530 subjects 
Table 2 Allelic frequencies of SNPs in normotensive and hypertensive subjects 
Table 3 Association between the SNPs and haplotypes of UTS2 gene and plasma urotensin 
II level 
Table 4 Effect of the SNPs, -605G>A, 143G>A and 3836C>T in UTS2 gene and the 
corresponding haplotypes on fasting plasma insulin, HOMA-IR and HOMA-β% 
Table 5 Effect of the SNPs, -11640G>A and -8515T>C in UTS2R gene and the 
cooresponding haplotypes on 2 hour plasma glucose level after oral glucose tolerance test and 
plasma cholesterol level  
Figure 1 A schematic diagram of the map of (a) UTS2 gene and (b) UTS2R gene showing 
the locations of the SNPs studied. Exons and intron are represented by grey boxes and thin 
lines respectively with their sizes indicated. 
Figure 2 Sequence of part of the UTS2 promoter. The nucleotides underlined with solid lines 
are the annealing sites of the primers, U2P3 and U2P2 for RFLP and those with dash lines are 
the restriction enzyme recognition sites. The locations of the two SNPs are indicated by the 
symbol (●). 
Figure 3  RFLP genotyping. (a) The -605G>A substitution eliminates a FokI site, producing 
a single fragment (375bp) instead of 2 smaller fragments (98 and 281bp). (b) The -788C>T 
substitution eliminates one of two MwoI sites, producing 2 fragments (134 and 244bp) 
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 instead of 3 fragments (19, 118 and 244bp).  
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 Table 1 
 
 Normotensive Hypertensive p-value 
N 306 224 - 
Sex (male:female) 155:151 123:101 0.332 
Age (yrs) 52.8±11.4 57.2±11.0 <0.001 
Regular alcohol consumption (%) 13.5 10.9 0.360 
Systolic pressure (mmHg) 116.2±11.9 144.3±18.4 <0.001 
Diastolic pressure (mmHg) 72.8±7.7 86.5±11.0 <0.001 
Weight (kg) 59.8±10.0 64.2±10.9 <0.001 
BMI (kg/m2) 23.2±3.0 25.0±3.3 <0.001 
Body fat (%) 27.2±7.2 30.3±7.5 <0.001 
Waist circumference (cm) 78.2±8.9 83.8±9.3 <0.001 
Plasma cholesterol (mmol/l) 5.2±0.8 5.4±0.9 0.001 
Plasma HDL cholesterol 
(mmol/L) 
1.5±0.4 1.4±0.4 0.009 
Plasma triglyceride (mmol/L) 1.2±0.7 1.6±1.1 <0.001 
Fasting plasma glucose (mmol/L) 5.1±0.7 5.4±1.1 0.003 
2-hour plasma glucose (mmol/L) 6.7±1.9 7.4±1.9 <0.001 
Fasting plasma insulin (mIU/L) 6.6 (6.3-7.0) 8.3 (7.7-8.9) <0.001 
HOMA-IR 1.5 (1.4-1.6) 2.0 (1.8-2.1) <0.001 
HOMA-β% 87.1 (81.8-92.9) 97.0 (89.5-105.2) 0.039 
Diabetes mellitus (%) 2.0 5.4 0.033 
Metabolic syndrome (%) 7.2 24.4 <0.001 
Antihypertensive treatment (%) - 45.1 - 
Data are expressed as mean ± SD or geometric mean with 95% confidence interval unless 




 Table 2  
 






χ2     p-value 
p-value 
UTS2:       
C 95.5% 97.5% 1.01 0.31 0.090 
T 4.5% 2.5%    
-1263C>T  
(rs7367534) 
      
C 89.7% 90.4% 0.39 0.53 0.709 
T 10.3% 9.6%    
-788C>T  
(Novel SNP) 
      
G 64.4% 67.4% 2.09 0.14 0.305 
A 35.6% 32.6%    
-605G>A  
(rs228647) 
      
G 64.4% 67.2% 2.28 0.12 0.342 
A 35.6% 32.8%    
143G>A  
(rs228648) 
      
C 69.1% 67.9% 1.14 0.28 0.662 
T 30.9% 32.1%    
3836C>T  
(rs2890565) 
      
UTS2R:       
G 71.3% 67.5% 0.41 0.52 0.079 
A 28.7% 32.5%    
-11640G>A 
(rs7502620) 
      
T 71.3% 68.0% 0.70 0.40 0.401 
C 28.7% 32.0%    
-8515T>C 
(rs7211435) 
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 Table 3   
Variants / 
haplotypes 
 N Plasma urotensin II 
(pmol/L) 
p-value 
-1263C>T CC 77 8.18±0.68 0.903 
 CT + TT 6 8.49±2.36  
     
-788C>T CC 68 8.43±0.73 0.469 
 CT + TT 15 7.19±1.46  
     
-605G>A GG 33 9.14±1.24 0.249 
 GA + AA 50 7.59±0.71  
     
143G>A GG 33 9.14±1.24 0.249 
 GA + AA 50 7.59±0.71  
     
3836C>T CC 45 6.63±0.73 0.008 
 CT + TT 38 10.07±1.07  
     
GGC Non-carrier 34 9.53±1.04 0.091 
 carrier 49 7.28±0.82  
     
GGT Non-carrier 46 6.84±0.75 0.020 
 carrier 37 9.89±1.09  
     
AAC Non-carrier 33 9.14±1.24 0.249 
 carrier 50 7.59±0.71  
Data are expressed as mean ± SEM 
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Table 4   
Variants / 
haplotypes 
 N plasma insulin (mIU/L) HOMA-IR HOMA-β% 
-605G>A GG 221 7.67 (7.14-8.24) 1.75 (1.62-1.89) 98.93 (91.29-107.22) 
 GA + AA 309 7.05 (6.63-7.49) 1.64 (1.53-1.75) 86.02 (80.70-91.69)*** 
      
143G>A GG 220 7.62 (7.10-8.19) 1.74 (1.61-1.88) 98.54 (90.92-106.81) 
 GA + AA 310 7.08 (6.66-7.52) 1.64 (1.54-1.76) 86.30 (80.96-92.00)** 
      
3836C>T CC 244 6.80 (6.33-7.30) 1.57 (1.45-1.69) 84.92 (78.73-91.60) 
 CT + TT 286 7.75 (7.30-8.24)*** 1.79 
(1.67-1.91)*** 
96.90 (90.64-103.59)** 
      
GGC Non-carrier 216 7.31 (6.81-7.84) 1.69 (1.57-1.82) 90.44 (83.70-97.72) 
 carrier 312 7.26 (6.83-7.73) 1.67 (1.56-1.79) 91.44 (85.54-97.74) 
      
GGT Non-carrier 249 6.79 (6.33-7.29) 1.56 (1.45-1.69) 84.92 (78.80-91.51) 
 carrier 279 7.75 (7.29-8.23)*** 1.79 (1.67-1.91)** 96.85 (90.51-103.64)** 
      
AAC Non-carrier 228 7.58 (7.06-8.14) 1.74 (1.61-1.87) 96.97 (89.40-105.18) 
 carrier 301 7.06 (6.64-7.51) 1.64 (1.53-1.75) 86.79 (81.44-92.49)* 
Data are expressed as geometric mean (95% CI) 
*p=0.03, **p=0.01, ***p<0.01 compared to non-carriers of minor allele of the particular 
single variant or non-carrier of the particular haplotype. 
Table 5   
Variants /   2 hour plasma glucose (mmol/L)
haplotypes  N Mean ± SE 
-11640G>A GG 138 6.53 ± 0.14* 
 GA + AA 150 7.04 ± 0.14* 
    
-8515T>C TT 138 6.53 ± 0.14* 
 TC + CC 150 7.04 ± 0.14* 
    
GT Non-carrier 24 6.80 ± 0.30 
 carrier 264 6.79 ± 0.11 
    
AC Non-carrier 138 6.53 ± 0.14* 
 carrier 150 7.04 ±0.14* 
*p=0.01 compared to non-carriers of minor allele of the particular single variant or 
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